Shouryadeep Srivastava

发表

Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

S. Kasner, M. Petrie, D. DeAngelo, 2022, Journal of Hematology & Oncology.

Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial.

G. Rosti, J. Cortes, M. Deininger, 2021, Blood.

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia

J. Dipersio, G. Rosti, J. Cortes, 2022, American journal of hematology.

Photoaffinity Labeling the Agonist Binding Domain of α4β4 and α4β2 Neuronal Nicotinic Acetylcholine Receptors with [125I] Epibatidine and 5[125I]A-85380

J. Steinbach, M. P. Blanton, M. Sanghvi, 2009 .

SHP656, a polysialylated recombinant factor VIII (PSA‐rFVIII): First‐in‐human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

P. Collins, A. Tiede, M. Wolfsegger, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Hydrophobic photolabeling studies identify the lipid-protein interface of the 5-HT3A receptor.

D. Lovinger, M. P. Blanton, Jonathan B. Cohen, 2009, Biochemistry.

Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model‐Informed Dose Selection for Pediatric Development

K. Venkatakrishnan, P. Diderichsen, N. Narasimhan, 2021, Journal of clinical pharmacology.

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

J. Dipersio, H. Kantarjian, G. Rosti, 2020 .

Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States.

Yuexi Wang, F. Neumann, Qisu Zhang, 2021, Cancer treatment and research communications.

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

G. Rosti, J. Cortes, M. Deininger, 2020 .

OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).

G. Rosti, M. Deininger, C. Chuah, 2021 .

Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) ALL.

M. Vignetti, H. Kantarjian, G. Martinelli, 2019, Journal of Clinical Oncology.